AfricaRegulatory
African Pharmaceutical Regulatory Intelligence
ABIRATERONE
9 registrations across 3 African markets— 5 active
Markets with ABIRATERONE
Recent registrations
| Brand / Product | Market | Holder | Status | Expires |
|---|---|---|---|---|
| ABERONE TABLET | 🇬🇭Ghana | — | expired | Oct 2026 |
| ABERONE TABLET | 🇬🇭Ghana | — | active | Oct 2026 |
| ABERONE TABLET | 🇬🇭Ghana | — | active | Oct 2026 |
| ABREMIA Comprimé / 250 mg | 🇹🇳Tunisia | HIKMA Pharmaceuticals | expired | Sept 2022 |
| ABIRATERONE ACETATE NEAPOLIS Comprimé / 250 mg | 🇹🇳Tunisia | NEAPOLIS PHARMA | expired | Jul 2021 |
| ZYTIGA Comprimé / 250 mg | 🇹🇳Tunisia | Janssen-Cilag International N.V | expired | Apr 2017 |
| ZYTIGA 250 mg | 🇿🇦South Africa | Janssen Pharmaceutica (Pty) Ltd | active | Jan 1900 |
| ABIRATERONE 250 mg ASCEND | 🇿🇦South Africa | Ascend Laboratories (Pty) Ltd | active | Jan 1900 |
| ZYBERA 250 mg | 🇿🇦South Africa | Teva Pharmaceuticals (Pty) Ltd | active | Jan 1900 |
ABIRATERONE in Africa — Regulatory Overview
ABIRATERONE is registered across 3 African markets with 9 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Ghana, Tunisia, South Africa. AfricaRegulatory refreshes this data daily from official government sources.
Of the 9 registrations, 5 (56%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.